KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBT Margin (2017 - 2025)

Historic EBT Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 3.39%.

  • Biomarin Pharmaceutical's EBT Margin fell 214200.0% to 3.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.95%, marking a year-over-year increase of 77300.0%. This contributed to the annual value of 18.98% for FY2024, which is 111900.0% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its EBT Margin stood at 3.39% for Q3 2025, which was down 214200.0% from 36.09% recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year EBT Margin high stood at 36.09% for Q2 2025, and its period low was 14.8% during Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's EBT Margin averaged around 9.58%, with its median value being 7.17% (2023).
  • In the last 5 years, Biomarin Pharmaceutical's EBT Margin surged by 210600bps in 2022 and then plummeted by -214200bps in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's EBT Margin stood at 14.8% in 2021, then soared by 78bps to 3.27% in 2022, then skyrocketed by 192bps to 2.99% in 2023, then soared by 659bps to 22.7% in 2024, then plummeted by -115bps to 3.39% in 2025.
  • Its EBT Margin was 3.39% in Q3 2025, compared to 36.09% in Q2 2025 and 31.95% in Q1 2025.